C4 Therapeutics Inc
NASDAQ:CCCC
US |
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
|
US |
Estee Lauder Companies Inc
NYSE:EL
|
Consumer products
|
|
US |
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
|
US |
Church & Dwight Co Inc
NYSE:CHD
|
Consumer products
|
|
US |
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
|
US |
American Express Co
NYSE:AXP
|
Financial Services
|
|
US |
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
|
US |
Visa Inc
NYSE:V
|
Technology
|
|
CN |
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
|
US |
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
|
US |
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
|
US |
Coca-Cola Co
NYSE:KO
|
Beverages
|
|
US |
Target Corp
NYSE:TGT
|
Retail
|
|
US |
Walt Disney Co
NYSE:DIS
|
Media
|
|
US |
Mueller Industries Inc
NYSE:MLI
|
Machinery
|
|
US |
PayPal Holdings Inc
NASDAQ:PYPL
|
Technology
|
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
52 Week Range |
1.18
11
|
Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
Johnson & Johnson
NYSE:JNJ
|
US | |
Estee Lauder Companies Inc
NYSE:EL
|
US | |
Exxon Mobil Corp
NYSE:XOM
|
US | |
Church & Dwight Co Inc
NYSE:CHD
|
US | |
Pfizer Inc
NYSE:PFE
|
US | |
American Express Co
NYSE:AXP
|
US | |
Nike Inc
NYSE:NKE
|
US | |
Visa Inc
NYSE:V
|
US | |
Alibaba Group Holding Ltd
NYSE:BABA
|
CN | |
3M Co
NYSE:MMM
|
US | |
JPMorgan Chase & Co
NYSE:JPM
|
US | |
Coca-Cola Co
NYSE:KO
|
US | |
Target Corp
NYSE:TGT
|
US | |
Walt Disney Co
NYSE:DIS
|
US | |
Mueller Industries Inc
NYSE:MLI
|
US | |
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
This alert will be permanently deleted.
Intrinsic Value
The intrinsic value of one CCCC stock under the Base Case scenario is 1.99 USD. Compared to the current market price of 4.93 USD, C4 Therapeutics Inc is Overvalued by 60%.
The Intrinsic Value is calculated as the average of DCF and Relative values:
Valuation Backtest
C4 Therapeutics Inc
Uncover deeper insights with the Valuation Backtest. Learn how current stock valuations stack up against historical averages to gauge true investment potential.
Start backtest now and learn if your stock is truly undervalued or overvalued!
Stock is trading at its lowest valuation over the past 5 years.
To access the results of this valuation backtest, please register an account with us. Registration is quick and gives you instant access to insights on 3 stocks per week for free.
The backtest for CCCC cannot be conducted due to limitations such as insufficient data or other constraints. Please select a different stock or adjust your settings.
Fundamental Analysis
Select up to 3 indicators:
Select up to 3 indicators:
Months
Months
Months
Months
Select up to 2 periods:
Revenue & Expenses Breakdown
C4 Therapeutics Inc
Balance Sheet Decomposition
C4 Therapeutics Inc
Current Assets | 273.2m |
Cash & Short-Term Investments | 255.6m |
Receivables | 10.3m |
Other Current Assets | 7.2m |
Non-Current Assets | 102.8m |
Long-Term Investments | 28.8m |
PP&E | 65.4m |
Other Non-Current Assets | 8.7m |
Current Liabilities | 43.3m |
Accounts Payable | 1.5m |
Accrued Liabilities | 19.2m |
Other Current Liabilities | 22.6m |
Non-Current Liabilities | 90.1m |
Other Non-Current Liabilities | 90.1m |
Earnings Waterfall
C4 Therapeutics Inc
Revenue
|
33.7m
USD
|
Operating Expenses
|
-150.6m
USD
|
Operating Income
|
-116.9m
USD
|
Other Expenses
|
11.4m
USD
|
Net Income
|
-105.5m
USD
|
Free Cash Flow Analysis
C4 Therapeutics Inc
USD | |
Free Cash Flow | USD |
CCCC Profitability Score
Profitability Due Diligence
C4 Therapeutics Inc's profitability score is 21/100. The higher the profitability score, the more profitable the company is.
Score
C4 Therapeutics Inc's profitability score is 21/100. The higher the profitability score, the more profitable the company is.
CCCC Solvency Score
Solvency Due Diligence
C4 Therapeutics Inc's solvency score is 58/100. The higher the solvency score, the more solvent the company is.
Score
C4 Therapeutics Inc's solvency score is 58/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
CCCC Price Targets Summary
C4 Therapeutics Inc
According to Wall Street analysts, the average 1-year price target for CCCC is 16.47 USD with a low forecast of 8.08 USD and a high forecast of 40.95 USD.
Dividends
Current shareholder yield for CCCC is .
Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?
Profile
Country
Industry
Market Cap
Dividend Yield
Description
C4 Therapeutics, Inc. engages in the development of targeted protein degradation science to develop a new generation of small molecule medicines used for treating diseases. The company is headquartered in Watertown, Massachusetts and currently employs 121 full-time employees. The company went IPO on 2020-10-02. The firm is focused on harnessing the body’s natural regulation of protein levels to develop therapeutic candidates to target and destroy disease-causing proteins for the treatment of cancer, neurodegenerative conditions and other diseases. The firm provides technology platform, Target ORiented ProtEin Degrader Optimizer (TORPEDO), to synthesize a new class of small molecule protein degraders that are designed to destroy disease-causing proteins, including targets previously considered to be undruggable. The Company’s lead product candidates, CFT7455, is an orally bioavailable degrader targeting IKZF1/3 for multiple myeloma (MM), peripheral T-cell lymphoma (PTCL), and mantle cell lymphoma (MCL). The firm is also developing CFT8634, an orally bioavailable degrader of a protein target called bromodomain containing 9 (BRD9), for synovial sarcoma and SMARCB1-deleted solid tumors.
Contact
IPO
Employees
Officers
The intrinsic value of one CCCC stock under the Base Case scenario is 1.99 USD.
Compared to the current market price of 4.93 USD, C4 Therapeutics Inc is Overvalued by 60%.